ofloxacin has been researched along with Gram-Negative Bacterial Infections in 70 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Gram-Negative Bacterial Infections: Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Compare two dosage strengths of levofloxacin in the treatment of acute bacterial sinusitis." | 9.12 | A trial of high-dose, short-course levofloxacin for the treatment of acute bacterial sinusitis. ( Anon, J; Kahn, J; Khashab, M; Paglia, M; Poole, M; Xiang, J, 2006) |
| "A randomized, double-blind, double-dummy, three-arm parallel design, multicentre study was conducted among adult patients with acute exacerbation of chronic bronchitis (AECB) in order to compare the efficacy and safety of two different doses of levofloxacin with cefuroxime axetil." | 9.09 | Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind study. ( Dolmann, A; Fiss, E; Maesen, FP; Shah, PM; Vetter, N; Wesch, R, 1999) |
| "An open, randomized, multinational, multicentre study was conducted to compare the efficacy, safety and tolerability of levofloxacin 500 mg twice daily with imipenem/cilastatin 1 g iv three-times daily in the treatment of hospitalized adult patients with clinically suspected bacteraemia/ sepsis." | 9.09 | Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomized trial. ( Geddes, A; Härkönen, M; Jacobs, F; Nowotny, I; Schonwald, S; Thaler, M, 1999) |
| "Thirty cirrhotic patients with spontaneous bacterial peritonitis were assigned to receive either intravenous (1 g/12 h) cefotaxime for 7 days (n=17) or intravenous (200 mg/12 h) ofloxacin for 2 days followed by oral (200 mg/12 h) ofloxacin for 5 days (n=13)." | 7.72 | Comparison of cefotaxime and ofloxacin in treatment of spontaneous bacterial peritonitis. ( Aslan, SL; Buyraç, Z; Colakoğlu, O; Sözmen, B; Taşkiran, B; Unsal, B, 2004) |
| "Compare two dosage strengths of levofloxacin in the treatment of acute bacterial sinusitis." | 5.12 | A trial of high-dose, short-course levofloxacin for the treatment of acute bacterial sinusitis. ( Anon, J; Kahn, J; Khashab, M; Paglia, M; Poole, M; Xiang, J, 2006) |
| "A randomized, double-blind, double-dummy, three-arm parallel design, multicentre study was conducted among adult patients with acute exacerbation of chronic bronchitis (AECB) in order to compare the efficacy and safety of two different doses of levofloxacin with cefuroxime axetil." | 5.09 | Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind study. ( Dolmann, A; Fiss, E; Maesen, FP; Shah, PM; Vetter, N; Wesch, R, 1999) |
| "An open, randomized, multinational, multicentre study was conducted to compare the efficacy, safety and tolerability of levofloxacin 500 mg twice daily with imipenem/cilastatin 1 g iv three-times daily in the treatment of hospitalized adult patients with clinically suspected bacteraemia/ sepsis." | 5.09 | Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomized trial. ( Geddes, A; Härkönen, M; Jacobs, F; Nowotny, I; Schonwald, S; Thaler, M, 1999) |
| "A total of 125 ambulatory women (85 premenopausal and 40 postmenopausal) who experienced 174 acute urinary tract infections with mainly gram-negative bacteria (99%) was randomized to receive a single dose, 2-tablet treatment with either ofloxacin (400 mg." | 5.07 | Single dose quinolone treatment in acute uncomplicated urinary tract infection in women. ( Pfau, A; Sacks, TG, 1993) |
| " radiobacter bacteremia treated with levofloxacin." | 3.74 | [A rare cause of catheter-related bacteremia: Rhizobium radiobacter]. ( Görümlü, G; Işikgoz Taşbakan, M; Karabulut, B; Pullukçu, H; Sanli, UA; Sipahi, OR; Tünger, A, 2008) |
| "A 48-year-old man presented with a corneal ulcer in his right eye and was treated with ofloxacin and fortified bacitracin ophthalmic solution." | 3.72 | Chryseobacterium meningosepticum keratitis. ( Bloom, AH; Davis, RG; Donnenfeld, ED; Perry, HD, 2003) |
| "Thirty cirrhotic patients with spontaneous bacterial peritonitis were assigned to receive either intravenous (1 g/12 h) cefotaxime for 7 days (n=17) or intravenous (200 mg/12 h) ofloxacin for 2 days followed by oral (200 mg/12 h) ofloxacin for 5 days (n=13)." | 3.72 | Comparison of cefotaxime and ofloxacin in treatment of spontaneous bacterial peritonitis. ( Aslan, SL; Buyraç, Z; Colakoğlu, O; Sözmen, B; Taşkiran, B; Unsal, B, 2004) |
| " In the UK chloramphenicol is commonly recommended as the drug of first choice for the treatment of superficial bacterial eye infections." | 3.69 | Fluoroquinolones for the eye. ( , 1994) |
| "Febrile neutropenia is an expected complication during treatment of aggressive hematological malignancies and hematopoietic cell transplantation." | 2.73 | The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit. ( Craig, M; Cumpston, AD; Devetten, MP; Ericson, SG; Hobbs, GR; Sarwari, AR, 2007) |
| "Both cancer centers differed in prophylactic antibiotic policies." | 2.69 | Bacteremia and fungemia in pediatric versus adult cancer patients after chemotherapy: comparison of etiology, risk factors and outcome. ( Foltinova, A; Kaiserova, E; Kiskova, M; Kovacicova, G; Krchnakova, A; Krcmery, V; Krupova, I; Kunova, A; Trupl, J; West, D, 1998) |
| " three times daily with dosage adjustment according to renal function and body weight (group 2)." | 2.67 | Empiric treatment of serious infections in patients with cancer: randomised comparison of two combinations. ( Maiche, AG; Teerenhovi, L, 1991) |
| " In particular, the deeper knowledge of kinetic-dynamic characteristics has allowed to highlight that high dosage approach in short term therapy might reveal as extremely interesting in a setting of critical patients." | 2.45 | [PK/PD profile and post-marketing surveillance of levofloxacin]. ( Pea, F, 2009) |
| "Levofloxacin is a fluoroquinolone antibiotic and is the optical S-(-) isomer of the racemic drug substance ofloxacin." | 2.40 | The clinical pharmacokinetics of levofloxacin. ( Chow, AT; Fish, DN, 1997) |
| "A case of septic arthritis in a 70-year-old man with chronic obstructive pulmonary disease (COPD) initially presenting with right knee pain, swelling and redness is reported." | 1.39 | [Septic monarthritis caused by Sphingomonas paucimobilis]. ( Burk, M; Dischereit, G; Lange, U; Storck-Müller, K, 2013) |
| "Gatifloxacin showed lower resistance levels than moxifloxacin." | 1.38 | [In vitro antibiotic susceptibility to fluoroquinolones]. ( Galvis, V; Rey, JJ; Tello, A; Villareal, D; Wong, CA, 2012) |
| "Septic pulmonary embolism (SPE) is an uncommon, but life-threatening event that is usually associated with extrapulmonary infections." | 1.37 | Tsukamurella tyrosinosolvens and Rhizobium radiobacter sepsis presenting with septic pulmonary emboli. ( Calista, F; Fadda, G; Fiori, B; Mignogna, S; Romano, L; Sali, M; Spanu, T; Zappacosta, B, 2011) |
| "Paronychia is a well-known, but difficult to treat cutaneous toxicity associated with epidermal growth factor receptor (EGFR) inhibitor therapy." | 1.36 | Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia. ( Eames, T; Grabein, B; Kroth, J; Wollenberg, A, 2010) |
| "Emerging evidence suggests that current fluoroquinolone dosing strategies may be inadequate to treat bloodstream infections caused by organisms classified as sensitive." | 1.35 | Effect of differences in MIC values on clinical outcomes in patients with bloodstream infections caused by gram-negative organisms treated with levofloxacin. ( Defife, R; Feinglass, JM; Postelnick, MJ; Scarsi, KK; Scheetz, MH, 2009) |
| " Efforts should be directed at modifying hospital policies for dosing of levofloxacin and DTCCs to prevent coadministration." | 1.33 | Coadministration of oral levofloxacin with agents that impair its absorption: potential impact on emergence of resistance. ( Barton, TD; Fishman, NO; Lautenbach, E; Quain, RD; Weiner, MG, 2005) |
| " pneumoniae, MPC results were below susceptible breakpoints and within clinically achievable and sustainable drug concentrations for >24 hours of the dosing interval against." | 1.33 | Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens. ( Blondeau, JM; Hansen, GT, 2005) |
| "Levofloxacin resistance was detected in 2 of 2,834 isolates (0." | 1.32 | Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States. ( Critchley, IA; Evangelista, AT; Jones, ME; Karlowsky, JA; Noel, GJ; Sahm, DF; Thornsberry, C, 2003) |
| "Ofloxacin is a quinolone administered to patients with severe infections." | 1.32 | Single-dose pharmacokinetics of ofloxacin during continuous venovenous hemofiltration in critical care patients. ( El Menyawi, I; Fuhrmann, V; Mittermayer, C; Ratheiser, K; Schenk, P; Thalhammer, F, 2003) |
| "Ciprofloxacin was the most potent study drug against the family of Enterobacteriaceae and Pseudomonas spp." | 1.30 | Antibacterial activity of moxifloxacin (Bay 12-8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility tests. ( Barry, AL; Brown, SD; Fuchs, PC, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 20 (28.57) | 18.2507 |
| 2000's | 37 (52.86) | 29.6817 |
| 2010's | 13 (18.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dischereit, G | 1 |
| Burk, M | 1 |
| Storck-Müller, K | 1 |
| Lange, U | 1 |
| Ullah, O | 1 |
| Khan, A | 1 |
| Ambreen, A | 1 |
| Ahmad, I | 1 |
| Akhtar, T | 1 |
| Gandapor, AJ | 1 |
| Khan, AM | 1 |
| Tanaseanu, C | 1 |
| Bergallo, C | 1 |
| Teglia, O | 1 |
| Jasovich, A | 1 |
| Oliva, ME | 1 |
| Dukart, G | 1 |
| Dartois, N | 1 |
| Cooper, CA | 1 |
| Gandjini, H | 1 |
| Mallick, R | 1 |
| Işikgoz Taşbakan, M | 1 |
| Görümlü, G | 1 |
| Pullukçu, H | 1 |
| Sanli, UA | 1 |
| Sipahi, OR | 1 |
| Karabulut, B | 1 |
| Tünger, A | 1 |
| Green, O | 1 |
| Murray, P | 1 |
| Gea-Banacloche, JC | 1 |
| Defife, R | 1 |
| Scheetz, MH | 1 |
| Feinglass, JM | 1 |
| Postelnick, MJ | 1 |
| Scarsi, KK | 1 |
| Passerini de Rossi, B | 1 |
| García, C | 1 |
| Calenda, M | 1 |
| Vay, C | 1 |
| Franco, M | 1 |
| Gupta, A | 1 |
| Swaroop, C | 1 |
| Agarwala, S | 1 |
| Pandey, RM | 1 |
| Bakhshi, S | 1 |
| Eames, T | 1 |
| Grabein, B | 1 |
| Kroth, J | 1 |
| Wollenberg, A | 1 |
| Kelesidis, T | 1 |
| Dien Bard, J | 1 |
| Humphries, R | 1 |
| Ward, K | 1 |
| Lewinski, MA | 1 |
| Uslan, DZ | 1 |
| Pea, F | 1 |
| Thabet, L | 1 |
| Memmi, M | 1 |
| Turki, A | 1 |
| Messadi, AA | 1 |
| Romano, L | 1 |
| Spanu, T | 1 |
| Calista, F | 1 |
| Zappacosta, B | 1 |
| Mignogna, S | 1 |
| Sali, M | 1 |
| Fiori, B | 1 |
| Fadda, G | 1 |
| Salman, S | 1 |
| Young, M | 1 |
| Van Sickels, JE | 1 |
| Rafat, C | 1 |
| Vimont, S | 1 |
| Ancel, PY | 1 |
| Xu-Dubois, YC | 1 |
| Mesnard, L | 1 |
| Ouali, N | 1 |
| Denis, M | 1 |
| Vandewalle, A | 1 |
| Rondeau, E | 1 |
| Hertig, A | 1 |
| Lorenzo Garde, L | 1 |
| Bolaños Rivero, M | 1 |
| Turégano García, Á | 1 |
| Martín Sánchez, AM | 1 |
| Wong, CA | 1 |
| Galvis, V | 1 |
| Tello, A | 1 |
| Villareal, D | 1 |
| Rey, JJ | 1 |
| Parra-Riffo, H | 1 |
| Lemus-Peñaloza, J | 1 |
| Gould, VC | 1 |
| Okazaki, A | 1 |
| Avison, MB | 1 |
| Chung, HS | 1 |
| Hong, SG | 1 |
| Kim, YR | 1 |
| Shin, KS | 1 |
| Whang, DH | 1 |
| Ahn, JY | 1 |
| Park, YJ | 1 |
| Uh, Y | 1 |
| Chang, CL | 1 |
| Shin, JH | 1 |
| Lee, HS | 1 |
| Lee, K | 1 |
| Chong, Y | 1 |
| Kherani, F | 1 |
| Kherani, A | 1 |
| Gehrs, KM | 1 |
| Heilskov, TW | 1 |
| Sutphin, JE | 1 |
| Wagoner, MD | 1 |
| Candel, FJ | 1 |
| López, R | 1 |
| Valdivia, A | 1 |
| Núñez, MJ | 1 |
| Roca-Arbonés, V | 1 |
| Picazo de la Garza, JJ | 1 |
| Karlowsky, JA | 1 |
| Thornsberry, C | 1 |
| Critchley, IA | 1 |
| Jones, ME | 1 |
| Evangelista, AT | 1 |
| Noel, GJ | 1 |
| Sahm, DF | 1 |
| Ko, WC | 1 |
| Chiang, SR | 1 |
| Lee, HC | 1 |
| Tang, HJ | 1 |
| Wang, YY | 1 |
| Chuang, YC | 1 |
| Bloom, AH | 1 |
| Perry, HD | 1 |
| Donnenfeld, ED | 1 |
| Davis, RG | 1 |
| Fuhrmann, V | 1 |
| Schenk, P | 1 |
| Mittermayer, C | 1 |
| El Menyawi, I | 1 |
| Ratheiser, K | 1 |
| Thalhammer, F | 1 |
| Smith, MD | 1 |
| Gradon, JD | 1 |
| Chou, SY | 1 |
| Tsai, CC | 1 |
| Kau, SC | 1 |
| Kau, HC | 1 |
| Hsu, WM | 1 |
| Taşkiran, B | 1 |
| Colakoğlu, O | 1 |
| Sözmen, B | 1 |
| Unsal, B | 1 |
| Aslan, SL | 1 |
| Buyraç, Z | 1 |
| Amoureux, MC | 1 |
| Rajapakse, N | 1 |
| Hegyi, E | 1 |
| Le, D | 1 |
| Grandics, P | 1 |
| Szathmary, S | 1 |
| Hoepelman, I | 1 |
| Lanzafame, A | 1 |
| Bonfiglio, G | 1 |
| Santini, L | 1 |
| Mattina, R | 1 |
| McKnight, AJ | 1 |
| Shaw, A | 1 |
| Goldsmith, CE | 1 |
| Clarke, L | 1 |
| Millar, BC | 1 |
| McCaughan, J | 1 |
| Elborn, JS | 1 |
| Reid, A | 1 |
| Moore, JE | 1 |
| Tash, K | 1 |
| Quain, RD | 1 |
| Barton, TD | 1 |
| Fishman, NO | 1 |
| Weiner, MG | 1 |
| Lautenbach, E | 1 |
| Hsueh, PR | 1 |
| Chen, WH | 1 |
| Luh, KT | 1 |
| Hansen, GT | 1 |
| Blondeau, JM | 2 |
| Poole, M | 1 |
| Anon, J | 1 |
| Paglia, M | 1 |
| Xiang, J | 1 |
| Khashab, M | 1 |
| Kahn, J | 1 |
| Alvarez-Lerma, F | 1 |
| Grau, S | 1 |
| Alvarez-Beltrán, M | 1 |
| Hassoun, A | 1 |
| Eiland, E | 1 |
| Legout, L | 1 |
| Senneville, E | 1 |
| Stern, R | 1 |
| Yazdanpanah, Y | 1 |
| Savage, C | 1 |
| Roussel-Delvalez, M | 1 |
| Rosele, B | 1 |
| Migaud, H | 1 |
| Mouton, Y | 1 |
| Bassetti, M | 1 |
| Righi, E | 1 |
| Rosso, R | 1 |
| Mannelli, S | 1 |
| Di Biagio, A | 1 |
| Fasce, R | 1 |
| Pallavicini, FB | 1 |
| Marchetti, F | 1 |
| Viscoli, C | 1 |
| Craig, M | 1 |
| Cumpston, AD | 1 |
| Hobbs, GR | 1 |
| Devetten, MP | 1 |
| Sarwari, AR | 1 |
| Ericson, SG | 1 |
| Noviello, S | 1 |
| Ianniello, F | 1 |
| Leone, S | 1 |
| Esposito, S | 1 |
| Chang, CY | 1 |
| Lee, YT | 1 |
| Liu, KS | 1 |
| Wang, YL | 1 |
| Tsao, SM | 1 |
| Lerner, J | 1 |
| Brumberger, V | 1 |
| Preac-Mursic, V | 1 |
| Savitskaia, KI | 1 |
| Tsar'kova, LN | 1 |
| Shanina, AG | 1 |
| Nasonov, VN | 1 |
| Solodilova, OE | 1 |
| Rusanova, EV | 1 |
| Beam, TR | 1 |
| Belliveau, P | 1 |
| Nightingale, CH | 1 |
| Quintiliani, R | 1 |
| Crowe, H | 1 |
| Gousee, G | 1 |
| Pfaller, MA | 1 |
| Barry, AL | 2 |
| Fuchs, PC | 2 |
| Spivey, IM | 1 |
| Pfau, A | 1 |
| Sacks, TG | 1 |
| Saenko, VF | 1 |
| Viktorov, AP | 1 |
| Golopykho, LI | 1 |
| Nichitaĭlo, ME | 1 |
| Gorshevikova, EV | 1 |
| Karachalios, GN | 1 |
| Nasiopoulou, DD | 1 |
| Bourlinou, PK | 1 |
| Reppa, A | 1 |
| Fish, DN | 1 |
| Chow, AT | 1 |
| Krupova, I | 1 |
| Kaiserova, E | 1 |
| Foltinova, A | 1 |
| Kovacicova, G | 1 |
| Kiskova, M | 1 |
| Krchnakova, A | 1 |
| Kunova, A | 1 |
| Trupl, J | 1 |
| West, D | 1 |
| Krcmery, V | 2 |
| Krupova, Y | 1 |
| Novotny, J | 1 |
| Sabo, A | 1 |
| Mateicka, F | 1 |
| Iwata, M | 1 |
| Tateda, K | 1 |
| Matsumoto, T | 1 |
| Furuya, N | 1 |
| Mizuiri, S | 1 |
| Yamaguchi, K | 1 |
| Shah, PM | 1 |
| Maesen, FP | 1 |
| Dolmann, A | 1 |
| Vetter, N | 1 |
| Fiss, E | 1 |
| Wesch, R | 1 |
| Brown, SD | 1 |
| Geddes, A | 1 |
| Thaler, M | 1 |
| Schonwald, S | 1 |
| Härkönen, M | 1 |
| Jacobs, F | 1 |
| Nowotny, I | 1 |
| Laskowski, R | 1 |
| Bjarnason, J | 1 |
| Stewart, C | 1 |
| Cunha, BA | 1 |
| Alexandrakis, G | 1 |
| Alfonso, EC | 1 |
| Miller, D | 1 |
| Reid, G | 1 |
| Habash, M | 1 |
| Vachon, D | 1 |
| Denstedt, J | 1 |
| Riddell, J | 1 |
| Beheshti, M | 1 |
| Ledney, GD | 1 |
| Elliott, TB | 1 |
| Landauer, MR | 1 |
| Vigneulle, RM | 1 |
| Henderson, PL | 1 |
| Harding, RA | 1 |
| Tom, SP | 1 |
| Soares-Weiser, K | 1 |
| Paul, M | 1 |
| Brezis, M | 1 |
| Leibovici, L | 1 |
| Gür, D | 1 |
| Kocagöz, T | 1 |
| Akalin, HE | 1 |
| Maiche, AG | 1 |
| Teerenhovi, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study Of The Efficacy And Safety Of Tigecycline Vs Levofloxacin To Treat Subjects Hospitalized With Community-Acquired Pneumonia[NCT00079885] | Phase 3 | 430 participants (Actual) | Interventional | 2003-11-30 | Completed | ||
| A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study Of The Efficacy And Safety Of Intravenous Tigecycline Vs Intravenous Levofloxacin To Treat Subjects Hospitalized With Community-Acquired Pneumonia[NCT00081575] | Phase 3 | 434 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| Contribution of Fast Molecular Bacterial Identification by Real-time PCR in Managing of Postoperative Acute Endophthalmitis[NCT02850653] | 150 participants (Anticipated) | Interventional | 2007-11-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for ofloxacin and Gram-Negative Bacterial Infections
| Article | Year |
|---|---|
[PK/PD profile and post-marketing surveillance of levofloxacin].
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Cohort Studies; Drug Resistance, Multiple, Bacteri | 2009 |
Severe levofloxacin-induced hypoglycaemia: a case report and literature review.
Topics: Aged; Anti-Bacterial Agents; Catheter-Related Infections; Drug Therapy, Combination; Enterococcus; G | 2012 |
[Endocarditis due to Stenotrophomonas maltophilia].
Topics: Aortic Valve Insufficiency; Disease Susceptibility; Drug Resistance, Multiple, Bacterial; Drug Thera | 2002 |
Bacteremia due to Comamonas species possibly associated with exposure to tropical fish.
Topics: Administration, Oral; Aged; Aged, 80 and over; Animals; Animals, Domestic; Anti-Infective Agents; Ba | 2003 |
[New fluoroquinolones: levofloxacin, moxifloxacin and gatifloxacin].
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gr | 2004 |
Levofloxacin in the treatment of ventilator-associated pneumonia.
Topics: Anti-Infective Agents; Cross Infection; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Of | 2006 |
Quinolone therapy in intensive care unit settings.
Topics: Administration, Oral; Aged; Ciprofloxacin; Clinical Protocols; Clinical Trials as Topic; Cross Infec | 1993 |
Oral ciprofloxacin, ofloxacin, and lomefloxacin as alternatives to intravenous antimicrobial therapy.
Topics: Administration, Oral; Anti-Bacterial Agents; Ciprofloxacin; Drug Costs; Drug Tolerance; Female; Fluo | 1993 |
The clinical pharmacokinetics of levofloxacin.
Topics: Anti-Infective Agents; Clinical Trials, Phase III as Topic; Drug Interactions; Gram-Negative Bacteri | 1997 |
Evidence based case report. Antibiotic treatment for spontaneous bacterial peritonitis.
Topics: Acute Disease; Anti-Bacterial Agents; Cefotaxime; Evidence-Based Medicine; Female; Gram-Negative Bac | 2002 |
13 trials available for ofloxacin and Gram-Negative Bacterial Infections
| Article | Year |
|---|---|
Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Female; Gram-Negative Bacterial I | 2008 |
Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Female; Gram-Negative Bacterial I | 2008 |
Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Female; Gram-Negative Bacterial I | 2008 |
Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Female; Gram-Negative Bacterial I | 2008 |
Randomized controlled trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low-risk febrile neutropenia.
Topics: Administration, Oral; Adolescent; Ambulatory Care; Amikacin; Amoxicillin-Potassium Clavulanate Combi | 2009 |
A trial of high-dose, short-course levofloxacin for the treatment of acute bacterial sinusitis.
Topics: Acute Disease; Adult; Aged; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Double-Blind Me | 2006 |
Efficacy of the combination of levofloxacin plus ceftazidime in the treatment of hospital-acquired pneumonia in the intensive care unit.
Topics: Aged; Anti-Bacterial Agents; Ceftazidime; Cross Infection; Drug Therapy, Combination; Female; Gram-N | 2006 |
The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteremia; Drug Administration Schedule; Drug Resist | 2007 |
[Use of ofloxacin in the treatment of infections of the lower respiratory tract].
Topics: Adolescent; Adult; Asthma; Bronchitis; Chronic Disease; Female; Gram-Negative Bacterial Infections; | 1994 |
Single dose quinolone treatment in acute uncomplicated urinary tract infection in women.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Ciprofloxacin; Female; Gram-Negative Bacterial Infect | 1993 |
Treatment of acute biliary tract infections with ofloxacin: a randomized, controlled clinical trial.
Topics: Anti-Infective Agents; Bacteremia; Ceftriaxone; Cephalosporins; Cholangitis; Cholecystitis; Escheric | 1996 |
Bacteremia and fungemia in pediatric versus adult cancer patients after chemotherapy: comparison of etiology, risk factors and outcome.
Topics: Adult; Analysis of Variance; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; A | 1998 |
Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bronchitis; Cefuroxime; Cephalosporins; Chron | 1999 |
Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomized trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacteremia; Cilastatin; Cilastati | 1999 |
Oral fluoroquinolone therapy results in drug adsorption on ureteral stents and prevention of biofilm formation.
Topics: Administration, Oral; Adsorption; Anti-Infective Agents; Anti-Infective Agents, Urinary; Biofilms; C | 2001 |
Empiric treatment of serious infections in patients with cancer: randomised comparison of two combinations.
Topics: Administration, Oral; Cefotaxime; Drug Synergism; Drug Therapy, Combination; Gram-Negative Bacterial | 1991 |
47 other studies available for ofloxacin and Gram-Negative Bacterial Infections
| Article | Year |
|---|---|
[Septic monarthritis caused by Sphingomonas paucimobilis].
Topics: Aged; Anti-Bacterial Agents; Arthritis, Infectious; Diagnosis, Differential; Gram-Negative Bacterial | 2013 |
Antibiotic Sensitivity pattern of Bacterial Isolates of Neonatal Septicemia in Peshawar, Pakistan.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacteri | 2016 |
[A rare cause of catheter-related bacteremia: Rhizobium radiobacter].
Topics: Adult; Agrobacterium tumefaciens; Anti-Bacterial Agents; Bacteremia; Bone Neoplasms; Catheterization | 2008 |
Sepsis caused by Elizabethkingia miricola successfully treated with tigecycline and levofloxacin.
Topics: Anti-Bacterial Agents; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Levofloxa | 2008 |
Effect of differences in MIC values on clinical outcomes in patients with bloodstream infections caused by gram-negative organisms treated with levofloxacin.
Topics: Adult; Aged; Anti-Bacterial Agents; Cohort Studies; Female; Gram-Negative Bacteria; Gram-Negative Ba | 2009 |
Activity of levofloxacin and ciprofloxacin on biofilms and planktonic cells of Stenotrophomonas maltophilia isolates from patients with device-associated infections.
Topics: Anti-Infective Agents; Argentina; Biofilms; Ciprofloxacin; Cross Infection; Drug Resistance, Multipl | 2009 |
Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Age | 2010 |
First report of treatment of Anaerobiospirillum succiniciproducens bloodstream infection with levofloxacin.
Topics: Aged, 80 and over; Anaerobiospirillum; Anti-Bacterial Agents; Bacteremia; DNA, Bacterial; DNA, Ribos | 2010 |
The impact of fluoroquinolones use on antibiotic resistance in an intensive care burn department.
Topics: Acinetobacter; Anti-Infective Agents; Burn Units; Ceftazidime; Ciprofloxacin; Drug Resistance, Multi | 2010 |
Tsukamurella tyrosinosolvens and Rhizobium radiobacter sepsis presenting with septic pulmonary emboli.
Topics: Actinomycetales; Actinomycetales Infections; Aged; Agrobacterium tumefaciens; Anti-Bacterial Agents; | 2011 |
Osteomyelitis after bilateral sagittal split osteotomy: case report and a review of the management.
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Bone Plates; Bone Screws; Clindamycin; Drainage; Enterob | 2011 |
Ofloxacin: new applications for the prevention of urinary tract infections in renal graft recipients.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Drug Resistance, Bacterial; Dru | 2011 |
[Intraperitoneal abscess for Eikenella corrodens].
Topics: Abdominal Abscess; Adenocarcinoma; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacteri | 2011 |
[In vitro antibiotic susceptibility to fluoroquinolones].
Topics: Acanthamoeba Keratitis; Anti-Bacterial Agents; Aza Compounds; Body Fluids; Ciprofloxacin; Colombia; | 2012 |
Coordinate hyperproduction of SmeZ and SmeJK efflux pumps extends drug resistance in Stenotrophomonas maltophilia.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bacterial Toxins; Ciprofloxacin; Gene Expression; Genes, | 2013 |
Antimicrobial susceptibility of stenotrophomonas maltophilia isolates from Korea, and the activity of antimicrobial combinations against the isolates.
Topics: Anti-Infective Agents; Gram-Negative Bacterial Infections; Hospitals, University; Humans; Levofloxac | 2013 |
Xanthomonas maltophilia endophthalmitis following penetrating corneal injury.
Topics: Amphotericin B; Cornea; Corneal Injuries; Drug Therapy, Combination; Endophthalmitis; Eye Infections | 2002 |
Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Azithromycin; Child; Child, Preschool; Drug Resistan | 2003 |
In vitro and in vivo activities of fluoroquinolones against Aeromonas hydrophila.
Topics: Aeromonas hydrophila; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Cefotaxi | 2003 |
Chryseobacterium meningosepticum keratitis.
Topics: Bacitracin; Cornea; Corneal Ulcer; Drug Therapy, Combination; Eye Infections, Bacterial; Flavobacter | 2003 |
Single-dose pharmacokinetics of ofloxacin during continuous venovenous hemofiltration in critical care patients.
Topics: Acute Kidney Injury; Adult; Aged; Anti-Infective Agents; Chromatography, High Pressure Liquid; Criti | 2003 |
Aeromonas hydrophila orbital cellulitis in a patient with myelodysplastic syndrome.
Topics: Aeromonas hydrophila; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Cefuroxime; Cellulitis; Gr | 2004 |
Comparison of cefotaxime and ofloxacin in treatment of spontaneous bacterial peritonitis.
Topics: Adult; Aged; Analysis of Variance; Cefotaxime; Dose-Response Relationship, Drug; Drug Administration | 2004 |
Endotoxin removal from whole blood by a novel adsorption resin: efficiency and hemocompatibility.
Topics: Adsorption; Anti-Infective Agents; Blood Coagulation Factors; Cell Count; Chromatography, Affinity; | 2004 |
In vitro activity of levofloxacin against recent Gram-negative nosocomial pathogens.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Cross Infection; Gram- | 2005 |
Comparison of in vitro susceptibilities to levofloxacin and ciprofloxacin with Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients in Northern Ireland.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Child; Ciprofloxacin; Cystic Fibrosis; Female; | 2005 |
Rahnella aquatilis bacteremia from a suspected urinary source.
Topics: Aged; Anti-Bacterial Agents; Gram-Negative Bacterial Infections; Humans; Infusions, Intravenous; Lev | 2005 |
Coadministration of oral levofloxacin with agents that impair its absorption: potential impact on emergence of resistance.
Topics: Administration, Oral; Adsorption; Aged; Anti-Bacterial Agents; Case-Control Studies; Cations, Divale | 2005 |
Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan.
Topics: Aminoglycosides; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Ca | 2005 |
Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteri | 2005 |
Effectiveness of flouroquinolone therapy for gram-negative infections within the intensive care unit setting.
Topics: Acinetobacter; Alabama; Ciprofloxacin; Drug Resistance, Bacterial; Enterobacter cloacae; Escherichia | 2006 |
Treatment of bone and joint infections caused by Gram-negative bacilli with a cefepime-fluoroquinolone combination.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bone Diseases, Infectious; Cefepime; Cephalos | 2006 |
[In vitro activity of prulifloxacin, levofloxacin and ciprofloxacin against urinary pathogens].
Topics: Anti-Bacterial Agents; Ciprofloxacin; Dioxolanes; Drug Resistance, Multiple, Bacterial; Fluoroquinol | 2006 |
Chromobacterium violaceum infection in Taiwan: a case report and literature review.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Chromobacterium; Female; Gram-Negative Bacteri | 2007 |
Fluoroquinolones for the eye.
Topics: Chloramphenicol; Ciprofloxacin; Eye Infections, Bacterial; Gram-Negative Bacterial Infections; Human | 1994 |
Severe diarrhea associated with Arcobacter butzleri.
Topics: Diarrhea; Doxycycline; Feces; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hu | 1994 |
Levofloxacin disk potency and tentative interpretive criteria for susceptibility tests.
Topics: Evaluation Studies as Topic; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positi | 1993 |
Criteria for use of ofloxacin and lomefloxacin in adult inpatients and outpatients.
Topics: Adult; Anti-Infective Agents; Fluoroquinolones; Gram-Negative Bacterial Infections; Humans; Infectio | 1993 |
[A clinical evaluation of the efficacy of using Zanocin (ofloxacin) in surgery].
Topics: Adult; Anti-Infective Agents; Biliary Fistula; Cefazolin; Cephalosporins; Cholangitis; Drug Evaluati | 1995 |
Aetiology, cost of antimicrobial therapy and outcome in neutropenic patients who developed bacteraemia during antimicrobial prophylaxis: a case-control study.
Topics: Amikacin; Amphotericin B; Antibiotic Prophylaxis; Bacteremia; Bacterial Infections; Case-Control Stu | 1998 |
Primary Shewanella alga septicemia in a patient on hemodialysis.
Topics: Anti-Bacterial Agents; Bacteremia; Cefazolin; Drug Therapy, Combination; Escherichia coli; Female; G | 1999 |
Antibacterial activity of moxifloxacin (Bay 12-8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility tests.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria, Aerobic; Ciprofloxacin; Fluoroquinolones; Gram-Negat | 1999 |
Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.
Topics: Anti-Infective Agents; Aza Compounds; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Gr | 2000 |
Community-acquired pneumonia: reality revisited.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Community-Acquired Infections; Doxycycline; Gram-Negat | 2000 |
Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Ciprofloxacin; Cornea; Corneal Ulcer; Drug R | 2000 |
Survival of irradiated mice treated with WR-151327, synthetic trehalose dicorynomycolate, or ofloxacin.
Topics: Adjuvants, Immunologic; Animals; Anti-Infective Agents; Ceftriaxone; Cephalosporins; Cord Factors; F | 1994 |
[In vitro activity of various antibiotic agents against gram-negative nosocomial bacteremia pathogens].
Topics: Amikacin; Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Cross Infection; Gram-Negative Bacteria; | 1992 |